Cramer's 'Mad Money' Recap: I Told You So
NEW YORK ( TheStreet) -- Today's rally rebuffed all the market's objections in spectacular fashion, Jim Cramer told "Mad Money" viewers Wednesday, showing just how wrong the bears were during the market selloff seven days ago.
Cramer said that just a week ago the markets were worried about a slowing U.S. economy, but today saw a good durable goods number along with price increases in both containerboard and steel, two very economically sensitive commodities.
He said the transports confirmed the data by rallying hard on the news, so much so that Cramer even recommended all three major airlines -- United Continental (UAL) , Delta Air Lines (DAL) and US Airways (LCC) .
The markets were also worried about Italy, noted Cramer, but JPMorgan Chase (JPM) , the large international bank, shrugged off those fears. Meanwhile, Joy Global (JOY) told investors that demand is not slowing in China, another fear last week.
The list of worries included a weak U.S. consumer, but that was rebuffed by just about all of retail heading higher Wednesday. Even the restaurants were strong, noted Cramer. Housing continues to be strong, as Toll Brothers (TOL) was able to make up lost ground from last week as well.
Finally, there were worries over the Federal Reserve and the massive government budget cuts known as sequestration. Cramer said Ben Bernanke put the Fed fears to rest, while the defense stocks are soaring in the face of looming budget cuts.
Add it all together and Cramer said the bears couldn't have been more wrong when they were in the midst of their panic selling last week.
In the "Executive Decision" segment, Cramer sat down with Dr. Harvey Berger, chairman and CEO of Ariad Pharmaceuticals (ARIA) , a stock that's risen 33% since Cramer last spoke to Berger in June 2012. Ariad recently received Food and Drug Administration approval for Iclusig, an orphan drug to treat leukemia that is expected to cost $115,000 per year.
Berger said that it has only taken five years for Ariad to go from its first clinical trials to FDA approval, which is a very short time period in the biotech world. He said that speaks to the difference Iclusig is making in the lives of its patients. The drug is expected to generate over $1 billion a year for Ariad in the next few years.
Berger noted that while Iclusig is currently used as a last resort for patients where other treatments have failed, the company has studies underway looking at its use as a first-line treatment, which would open up its possibilities greatly. He said the main challenge for Ariad now is educating doctors on its safety and performance.